11:54:53 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Scandinavian Chemotech är ett forskningsbolag. Idag specialiserar sig bolaget inom kemoterapi (ECT) vid behandling utav olika cancerformer. Bolagets produkt baseras på elektrokemoterapi som skickar elektroniska impulser under behandlingen för att lättare kunna nå cellernas DNA och därmed öka möjligheten till en bättre behandling. Behandlingen kan användas för såväl hudcancer som tumörer. Huvudkontoret ligger i Lund.

Kalender

2022-03-08 Bokslutskommuniké 2021
2021-11-02 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning CMOTEC B 0.00 SEK
2021-05-24 Årsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-03-08 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning CMOTEC B 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-13 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-12 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CMOTEC B 0.00 SEK
2019-05-08 Kvartalsrapport 2019-Q1
2019-05-08 Årsstämma 2019
2019-03-19 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Extra Bolagsstämma 2018
2018-03-01 Ordinarie utdelning CMOTEC B 0.00 SEK
2018-02-28 Årsstämma 2018
2018-01-30 Bokslutskommuniké 2017
2017-05-31 Extra Bolagsstämma 2017
2021-09-06 21:30:00

Scandinavian ChemoTech AB (publ) ("ChemoTech" or "the Company") hereby announces that the Company has carried out a directed new share issue which will provide the Company with approximately MSEK 2.5. The capital injection will be used to repay loans.

The Board of ChemoTech has, with the support of authorisation from the Annual General Meeting on May 24, 2021, decided on a directed new issue of 121,417 Series B shares at the same terms and conditions as the previously closed directed share issue which provided the Company with approximately MSEK 18. Thus, the subscription price amounts to SEK 20.59 per share. The right to subscribe for the new shares shall vest in the lenders Qualcon Aktiebolag which has subscribed for 97,134 shares and Råsunda Förvaltning Aktiebolag which has subscribed for 24,283 shares.

It is the Board's assessment that the subscription price is market-based and reflects prevailing market conditions and demand. The reason why the share issue has been carried out, and the reasons for the deviation from the shareholders' preferential rights is that it provides the company with working capital in a sufficiently time- and cost-effective manner and take advantage of future opportunities to bring in long-term stable owners and finance the Company's growth strategy.

The directed share issue issues a dilution of approximately 1.26 percent of the number of shares and approximately 1.04 percent of the votes in the Company calculated according to the directed share issue. Following the registration of the directed share issue with the Swedish Companies Registration Office, the total number of outstanding shares will increase by 121,417, from 9,507,638 to 9,629,055 and the number of votes will increase by 121,417, from 11,607,638 votes to 11,729,055 votes. The share capital will increase by SEK 60,708.50, from 4,753,819.00 to 4,814,527.50.

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-09-2021 21:30 CET.